1. Scrip
  2. >>Focus On Asia
  3. >>China

Hengrui, Affiliate Reistone In Apparent Dispute Over China Ivarmacitinib NDAs

Promises, Perils Of A Seemingly Dream Partnership

 
• By Brian Yang

The future fate of Jiangsu Hengrui’s new drug discovery and development subsidiary may provide some tips on what’s ahead for the Chinese biopharma sector.

Jiangsu Hengrui Medicine
Hengrui and affiliate Reistone at loggerheads over NDA strategy? • Source: Shutterstock

Reistone Biopharma Company Limited, based in Shanghai’s Zhangjiang Hi-Tech Park, has become the latest innovative biotech in China to run into difficulties amid a worsening capital crunch and a rights dispute with its majority stakeholder, Jiangsu Hengrui Medicine Co., Ltd.

On 14 September, a social media post created ripples across the country’s biopharma sector as it suggested Hengrui was seemingly moving to dissolve the smaller, autoimmune-focused company

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from China

More from Focus On Asia

Transient FY26 For Syngene But Momentum In China +1 Projects

 
• By Anju Ghangurde

As biopharma derisks its business with China ‘rebalancing’ strategies, Syngene could convert majority of such pilots into full program contracts amid a challenging FY2025. The CRDMO also expects business discussions pertaining to a newly acquired US biologics site to mature into commercial opportunities.

DIA Korea: Medical Turmoil, Global Factors Blunt Korea’s Trial Edge

 
• By Jung Won Shin

DIA Korea hears how multiple domestic and global factors are affecting the environment for clinical trials in South Korea, and what actions may be taken to address this.

Zai’s R&D Head Touts ‘Beauty’ Of Novel Internal Assets

 
• By Dexter Jie Yan

Two potentially first-in-class molecules signify Zai Lab’s renewed drive for the in-house discovery of drugs that it requires “to be innovative, differentiated and to have the potential to make a big difference for patients,” its global R&D head tells Scrip.